OSMT Key Statistics, Chart & Performance
The current stock price of OSMT is 1.11 null. In the past month the price increased by 12.8%. In the past year, price decreased by -75.11%.
OSMT Latest News, Press Relases and Analysis
OSMT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.73 | 971.39B | ||
| JNJ | JOHNSON & JOHNSON | 20.38 | 509.76B | ||
| MRK | MERCK & CO. INC. | 11.38 | 248.95B | ||
| PFE | PFIZER INC | 8.08 | 146.98B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.99 | 106.69B | ||
| ZTS | ZOETIS INC | 18.72 | 52.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.34 | 22.16B | ||
| VTRS | VIATRIS INC | 5 | 13.42B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.18 | 10.58B | ||
| CORT | CORCEPT THERAPEUTICS INC | 99.99 | 9.26B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.47B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.93B |
Related stock screener links
About OSMT
Company Profile
Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 302 full-time employees. The company went IPO on 2018-10-12. The firm is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The firm sells portfolio products consisting of promoted products and non-promoted products, which incorporate its Osmodex drug delivery system. The Company’s Osmodex drug delivery system uses osmotic pressure to provide a controlled drug release and is adaptable to many different combinations of immediate-release, extended-release and controlled- or delayed-release formulations that contain one or more drugs. The Company’s non-promoted product portfolio includes methylphenidate ER and venlafaxine extended-release tablets (VERT) as well as ANDAs and prescription dietary supplements. Its promoted products are led by Divigel and M-72 (methylphenidate hydrochloride extended-release tablets, 72 mg).
Company Info
OSMOTICA PHARMACEUTICALS PLC
400 Crossing Blvd
Bridgewater NEW JERSEY 08807 US
CEO: Brian Markison
Employees: 302
Phone: 19088091300.0
OSMOTICA PHARMACEUTICALS PLC / OSMT FAQ
What does OSMT do?
Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 302 full-time employees. The company went IPO on 2018-10-12. The firm is focused on the developing and commercialization of specialty products that target markets with underserved patient populations. The firm sells portfolio products consisting of promoted products and non-promoted products, which incorporate its Osmodex drug delivery system. The Company’s Osmodex drug delivery system uses osmotic pressure to provide a controlled drug release and is adaptable to many different combinations of immediate-release, extended-release and controlled- or delayed-release formulations that contain one or more drugs. The Company’s non-promoted product portfolio includes methylphenidate ER and venlafaxine extended-release tablets (VERT) as well as ANDAs and prescription dietary supplements. Its promoted products are led by Divigel and M-72 (methylphenidate hydrochloride extended-release tablets, 72 mg).
Can you provide the latest stock price for OSMOTICA PHARMACEUTICALS PLC?
The current stock price of OSMT is 1.11 null. The price decreased by -1.77% in the last trading session.
Does OSMOTICA PHARMACEUTICALS PLC pay dividends?
OSMT does not pay a dividend.
How is the ChartMill rating for OSMOTICA PHARMACEUTICALS PLC?
OSMT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of OSMT stock?
OSMOTICA PHARMACEUTICALS PLC (OSMT) has a market capitalization of 70.07M null. This makes OSMT a Micro Cap stock.
OSMT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to OSMT. When comparing the yearly performance of all stocks, OSMT is a bad performer in the overall market: 92.8% of all stocks are doing better.
OSMT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OSMT. OSMT may be in some trouble as it scores bad on both profitability and health.
OSMT Financial Highlights
Over the last trailing twelve months OSMT reported a non-GAAP Earnings per Share(EPS) of -1.59. The EPS decreased by -72.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -150.14% | ||
| ROA | -100.12% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
OSMT Forecast & Estimates
10 analysts have analysed OSMT and the average price target is 5.87 null. This implies a price increase of 428.38% is expected in the next year compared to the current price of 1.11.
For the next year, analysts expect an EPS growth of 18.29% and a revenue growth -89.33% for OSMT